Loading stock data…
Eli Lilly and Company (LLY)
$1206.58-1.55 (-0.13%)
Market OpenUpdated 11:14 AM EDT
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eli Lilly and Company in the Healthcare sector is trading at $1,210.29 with a market capitalization of $979.6B. Wall Street consensus targets $1,222.62 (29 analysts), implying a +1.0% move over the next 12 months. The stock is currently near its 52-week high of $1,238.00, remaining 24.0% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $19.80B↑ | $19.29B↑ | $17.60B↑ | $15.56B↑ | $12.73B |
| Gross Profit | $16.22B↑ | $15.92B↑ | $14.59B↑ | $13.11B↑ | $10.50B |
| Operating Income | $9.78B↑ | $8.99B↑ | $8.39B↑ | $7.02B↑ | $5.30B |
| Net Income | $7.40B↑ | $6.64B↑ | $5.58B↓ | $5.66B↑ | $2.76B |
Peer Comparison
JNJUNHPFE
Fundamentals
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$979.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
39.07
Beta
Defensive asset. Lower volatility than the S&P 500.
0.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.54%
ROE
Elite ROE. Management converts capital into profit efficiently.
81.02%
Volume
Today's trading volume
1.40M
Recent News
Dow Jones Futures Rise On U.S.-Iran News; Market At Tipping Point
The U.S. and Iran reportedly have agreed to halt tit-for-tat attacks. Tesla sales and the June jobs report on are on tap.
Is Eli Lilly and Company (LLY) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?
Eli Lilly and Company (NYSE:LLY) is among the Best Healthcare Stocks Stocks. On June 23, Reuters reported that Eli Lilly and Company (NYSE:LLY) expects to launch its oral weight-loss drug across Europe and Britain in the second half of 2026 or early 2027. Executive Vice President Patrik Jonsson said the company will start targeting patients paying […]
Eli Lilly (LLY) and BioArctic AB Enter into Research and Collaboration Agreement
Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration agreement regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. Management […]
Here’s What the Street Thinks About Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price target on the stock to $1,232 from $1,119 and maintained an Outperform rating on the shares. In a separate development, […]
Eli Lilly (LLY) Wins EMA Backing For Jaypirca In Chronic Lymphocytic Leukemia
Eli Lilly's cancer drug Jaypirca received a positive opinion from the European Medicines Agency regarding its use in chronic lymphocytic leukemia. The opinion supports potential use of Jaypirca across all lines of therapy for CLL in Europe. The recommendation is based on Phase 3 clinical trial data and now moves to European Commission review. Eli Lilly (NYSE:LLY) is best known recently for its GLP-1 portfolio, and oncology remains an important part of the business. The EMA's positive view...